XB3-001 XB3-001: If money has been the reason this program has stalled, why hasn't the company leveraged its contacts to find capital from friendly entities?
Our board member, David Wirzer, is EVP and CIO at conneticut innovations (CI). Surely a man of his stature could help raise enough non-dilutive capital for a Phase 1 trial ($10,000,000?) to move things forward, especially considering the technology has never failed.
Either the sources of capital don't like what we have (Why?), or we're not active enough.
Let's make it happen.
https://www.bioasis.us/about/board-of-directors/david-m-wurzer/
https://ctinnovations.com/obtain-funding/venture-solutions/connecticut-bioscience-innovation-fund/
"Connecticut Innovations will make investments from the $200 million CBIF over the next 10 years in the form of grants, equity investments and loans to speed commercializable bioscience breakthroughs to market. Startups and early-stage businesses may apply for secured convertible loans or equity. "